{"analyses":[{"ciLowerLimit":"0.041","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.334","groupDescription":"The differential benefit in prediction of Overall Survival occurs at the smallest measure such that Arm I (standard chemoradiotherapy) becomes superior to Arm II(experimental chemoradiotherapy)\n\nUsing the Cox:\n\nHR\\_BvsA (SUV) = exp(β2 +β3 \\*SUV) and B is better than A when β2 +β3 \\*SUV=0 the cutoff is when HR=1","groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.235"},{"ciNumSides":"TWO_SIDED","groupDescription":"Estimate Min Hazard (cutoff) for ΔSUVpeak between arms. The differential benefit in prediction of Overall Survival occurs at the smallest measure (of ΔSUVpeak) such that Arm I (standard chemoradiotherapy) becomes superior to Arm II(experimental chemoradiotherapy)\n\nUsing the Cox:\n\nHR\\_BvsA (SUV) = exp(β2 +β3 \\*SUV) and B is better than A when β2 +β3 \\*SUV=0 the cutoff is when HR=1","groupIds":["OG001","OG002"],"nonInferiorityComment":"min ΔSUVpeak such that differential benefit in prediction of Overall Survival occurs at the smallest measure where Arm I becomes superior to Arm II","nonInferiorityType":"OTHER","paramType":"ΔSUVpeak representing Min Hazard","paramValue":"-54.30"},{"ciLowerLimit":"0.524","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.737","groupDescription":"The differential benefit in prediction of PFS occurs at the smallest measure such that Arm I (standard chemoradiotherapy) becomes superior to Arm II(experimental chemoradiotherapy)\n\nUsing the Cox:\n\nHR\\_BvsA (SUV) = exp(β2 +β3 \\*SUV) and B is better than A when β2 +β3 \\*SUV=0 the cutoff is when HR=1","groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.954"},{"ciNumSides":"TWO_SIDED","groupDescription":"Estimate Min Hazard (cutoff) for ΔSUVpeak between arms. The differential benefit in prediction of PFS occurs at the smallest measure (of ΔSUVpeak) such that Arm I (standard chemoradiotherapy) becomes superior to Arm II(experimental chemoradiotherapy)\n\nUsing the Cox:\n\nHR\\_BvsA (SUV) = exp(β2 +β3 \\*SUV) and B is better than A when β2 +β3 \\*SUV=0 the cutoff is when HR=1","groupIds":["OG001","OG002"],"nonInferiorityComment":"min ΔSUVpeak such that differential benefit in prediction ofPFS occurs at the smallest measure where Arm I becomes superior to Arm II","nonInferiorityType":"OTHER","paramType":"ΔSUVpeak representing Min Hazard","paramValue":"-13.20"},{"ciLowerLimit":"0.304","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.482","groupDescription":"The differential benefit in prediction of LCCS occurs at the smallest measure such that Arm I (standard chemoradiotherapy) becomes superior to Arm II(experimental chemoradiotherapy)\n\nUsing the Cox:\n\nHR\\_BvsA (SUV) = exp(β2 +β3 \\*SUV) and B is better than A when β2 +β3 \\*SUV=0 the cutoff occurs when HR=1","groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.672"},{"ciNumSides":"TWO_SIDED","groupDescription":"Estimate Min Hazard (cutoff) for ΔSUVpeak between arms. The differential benefit in prediction of LCCS occurs at the smallest measure (of ΔSUVpeak) such that Arm I (standard chemoradiotherapy) becomes superior to Arm II(experimental chemoradiotherapy)\n\nUsing the Cox:\n\nHR\\_BvsA (SUV) = exp(β2 +β3 \\*SUV) and B is better than A when β2 +β3 \\*SUV=0 the cutoff is when HR=1","groupIds":["OG001","OG002"],"nonInferiorityComment":"min ΔSUVpeak such that differential benefit in prediction of LCCS occurs at the smallest measure where Arm I becomes superior to Arm II","nonInferiorityType":"OTHER","paramType":"ΔSUVpeak representing Min Hazard","paramValue":"-5.547"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.23","value":"-34.71"},{"groupId":"OG001","spread":"27.07","value":"-44.13"},{"groupId":"OG002","spread":"63.17","value":"-29.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Alive (OS) : True"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.37","value":"-42.62"},{"groupId":"OG001","spread":"34.13","value":"-34.43"},{"groupId":"OG002","spread":"22.99","value":"-46.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"47"}],"units":"Participants"}],"title":"Alive (OS) : False"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.77","value":"-44.36"},{"groupId":"OG001","spread":"31.93","value":"-40.46"},{"groupId":"OG002","spread":"22.31","value":"-47.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"Progression Free (PFS) : True"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.68","value":"-38.82"},{"groupId":"OG001","spread":"31.97","value":"-37.44"},{"groupId":"OG002","spread":"44.21","value":"-39.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"61"}],"units":"Participants"}],"title":"Progression Free (PFS) : False"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.02","value":"-39.15"},{"groupId":"OG001","spread":"25.90","value":"-42.35"},{"groupId":"OG002","spread":"57.54","value":"-37.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"32"}],"units":"Participants"}],"title":"Lung Cancer Cause-specific Survival (LCCS) True"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.65","value":"-40.34"},{"groupId":"OG001","spread":"35.71","value":"-34.88"},{"groupId":"OG002","spread":"22.49","value":"-43.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"39"}],"units":"Participants"}],"title":"Lung Cancer Cause-specific Survival (LCCS): False"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"71"}],"units":"Participants"}],"description":"Relative change in SUVpeak defined as ΔSUVpeak = (during-treatment SUVpeak - baseline SUVpeak)/baseline SUVpeak x 100%), Outcomes evaluated at 5 years. Overall Survival (OS): True if Alive 5 years from registration Progression Free Survival (PFS): True if Alive and no Progression 5 years from registration Lung Cancer Cause-specific Survival (LCCS): True if Alive and no Lung Cancer 5 years from registration","dispersionType":"Standard Deviation","groups":[{"description":"Patients undergo chemoradiotherapy as defined for the arm of the study to which they were randomized.\n\n18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study","id":"OG000","title":"Both Arms"},{"description":"Patients undergo standard radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FMISO-PET imaging at baseline\n\n18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study\n\nCarboplatin: Given IV\n\nExternal Beam Radiation Therapy: Undergo radiotherapy","id":"OG001","title":"Arm I (Standard Chemoradiotherapy)"},{"description":"Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.\n\n18F-Fluoromisonidazole: Participants enrolled at institutions participating in the FMISO correlative study undergo FMISO-PET prior to treatment\n\nCarboplatin: Given IV\n\nComputed Tomography: Undergo FDG PET/CT\n\nComputed Tomography: Undergo FMISO PET/CT (Correlative studies)\n\nFludeoxyglucose F-18: Undergo FDG PET/CT\n\nImage-Guided Adaptive Radiation Therapy: Undergo individualized adaptive radiotherapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nPositron Emission Tomography: Undergo FDG PET/CT\n\nPositron Emission Tomography: Undergo FMISO PET/CT (Correlative studies)","id":"OG002","title":"Arm II (Experimental Chemoradiotherapy)"}],"paramType":"MEAN","populationDescription":"Number analyzed represents the sample population having the specified (Row title) condition For example: of the 107 participants, 38 were alive after 5 years and had a ΔSUVpeak=-34.71","reportingStatus":"POSTED","timeFrame":"Baseline to up to 5 years after randomization","title":"Relative Change in SUV Peak From the Baseline to the During-treatment FDG PET/CT Prediction of the Differential Benefit of the Adaptive Therapy (ECOG-ACRIN)","type":"SECONDARY","unitOfMeasure":"percent change"}